mality as the threshold, the sensitivity, specificity, and positive and negative predictive values were calculated against histologically diagnosed high-grade squamous intraepithelial lesions (HSILs). RESULTS: Among 617 men recruited, the median age was 49 years (range, 35-79 years) and 35.7% were positive for the human immunodeficiency virus. Overall, the sensitivity of cytology was 83.2%, the specificity was 52.6%, the positive predictive value was 45.8%, and the negative predictive value was 86.7%. Specificity improved with increasing age (P for trend 5.041). Sensitivity was significantly higher in men with >1 anal octant of biopsy-confirmed HSIL (92.9% vs 77.7%; P 5 .010), and in those who had 10 metaplastic cells present on their cytology slides (87.5% vs 70.2%; P 5 .007). CONCLUSIONS: Anal cytology was found to have a higher specificity in older men while maintaining sensitivity. Sensitivity was higher among those with more extensive HSILs and men with metaplastic cells present on cytology. Cancer Cytopathol 2016;124:415-24.
INTRODUCTION
The incidence of anal cancer has increased in developed nations over the past 3 decades, but remains uncommon in the general population. [1] [2] [3] [4] [5] Certain populations have a greatly increased risk, including homosexual men, individuals with the human immunodeficiency virus (HIV), and women with previous genital human papillomavirus (HPV)-related disease. [6] [7] [8] [9] [10] [11] Anal squamous cell carcinoma shares several similarities with its cervical counterpart. Both have a causal association with high-risk HPV (HR-HPV), a presumed origin at a mucosal transformation zone, and a stage of intraepithelial cancer precursor (high-grade squamous intraepithelial lesion [HSIL] ) that can be detected by exfoliative cytology. 12 Well-organized screening programs have led to marked reductions in the incidence of cervical cancer. 3, 13, 14 It has been proposed that cytology-based anal cancer screening programs may similarly lead to a reduction in anal cancer incidence. To the best of our knowledge, such programs have been implemented in a limited number of settings, mostly in clinical settings providing care to homosexual men with HIV. 12, 15 As with cervical screening, individuals who have a degree of anal cytological abnormality above a specific threshold are referred for a diagnostic test, in this case high-resolution anoscopy (HRA)-guided biopsy, for histological assessment. To our knowledge, there have been relatively few studies of the performance of anal cytology tests for the detection of histologically confirmed HSILs. Recent reviews have highlighted the wide variations in the reported sensitivity and specificity of cytology in the detection of histologically confirmed anal HSILs. [16] [17] [18] The majority of these studies are based on small clinic-based samples of homosexual men with HIV, and what to our knowledge is the largest previous study included only 401 patients. 19 Analysis of screening test sensitivity requires that the diagnostic test (HRA) is performed on all study participants, not just those who screen positive, to identify false-negative cases. However, such studies are uncommon, most likely because of the researchers' reluctance to subject study volunteers to this relatively invasive diagnostic test. To our knowledge, only 6 studies that have performed liquidbased anal cytology and HRA at the same visit and recruited >100 participants have been reported to date (Table 1) . [19] [20] [21] [22] [23] [24] In the current study, we reported the performance of liquid-based anal cytology in the detection of histological HSILs at the time of the baseline visit among a cohort of HIV-negative and HIV-positive homosexual men in Sydney, New South Wales, Australia. All men underwent the screening anal cytology test and the diagnostic HRA at the same study visit.
MATERIALS AND METHODS

Participants
Participants were men taking part in the Study of the Prevention of Anal Cancer (SPANC) study. The methods of the study have been described in detail elsewhere. 25 Briefly, the SPANC study is an ongoing longitudinal study of the natural history of anal HPV infection and its associated anal squamous cellular abnormalities. Men who were aged 35 years and reported having sex with another man in their lifetime were eligible. Those who had a previous HRA or a history of anal cancer were excluded. Signed informed consent was provided by all participants. Ethics approval was granted by the Human Research Ethics Committees at the St. Vincent's Hospital in Sydney and the University of New South Wales. Participants were recruited mainly from communitybased settings in Sydney, including gay community social events and organizations, as well as referrals from other participants. In addition, approximately 35% of HIVpositive and 5% of HIV-negative men were recruited through clinics. Clinic-based  395  54  81  37  30  85  Salit 2010   19   Clinic-based  401  100  84  39  31  88  Wentzensen 2012   22   Clinic-based  363  100  89  39  31  92  Phanuphak 2013   23   Clinic-based  246  50  19  88  20  87  Sendagorta 2015   24   Clinic-based  101  100  83  41  55  73 Abbreviations: 1, positive; -, negative; HIV, human immunodeficiency virus; NPV, negative predictive value; PPV, positive predictive value. a Including studies that recruited >100 participants and performed screening cytology and diagnostic high-resolution anoscopy on all participants.
Anal Cytology
A Dacron swab moistened with tap water was used to sample the anal canal without the aid of an anoscope by the study clinician. Immediately after sampling, the swab was rinsed in a vial containing 20 mL of PreservCyt fixative medium (Hologic Inc, Marlborough, Mass). At a specialist anogenital pathology laboratory, a ThinPrep slide (Hologic Inc) was produced and manually screened by an experienced study cytologist. One of the 3 study pathologists was responsible for final reporting using The Bethesda System 2001 criteria and terms. A "satisfactory" slide was defined as having at least 2000 nucleated squamous cells. 26 
HRA and Histology
HRA was performed immediately after the anal cytology collection. Biopsies of visual abnormalities suspicious of HPV-related lesions were taken and formalin-fixed for processing and histopathological assessment. At the same laboratory in which cytological assessments were conducted, hematoxylin and eosin-stained slides of biopsy specimens were prepared and examined by 1 of the 3 experienced pathologists. Reporting of the biopsies was performed blinded to the cytology result and in accordance with criteria, terminology, and recommendations of the Lower Anogenital Squamous Terminology (LAST) Standardization Project. 27, 28 Results were reported as negative, exophytic LSIL, flat LSIL, HSIL-anal intraepithelial neoplasia grade 2 (AIN2), HSIL-anal intraepithelial neoplasia grade 3 (AIN3), or squamous cell carcinoma. As recommended by LAST, p16INK4a (p16) immunostaining was used to confirm all HSIL-AIN2 diagnoses. When hematoxylin and eosin-stained biopsies were considered to represent HSIL-AIN2, p16 immunostaining was performed on an unstained spare slide. Biopsies that were p16 positive were then finally confirmed as HSIL-AIN2, and p16-negative biopsies were then reported as LSIL or negative, depending on other criteria. When multiple biopsies were obtained, the most severe result was used as the histological diagnosis in the analysis. Biopsies were not obtained in participants who were assessed as having no visual abnormalities suggestive of SIL on HRA examination. These men were classified as being negative for SILs.
Statistical Analyses
Statistical analyses were performed using Stata statistical software (version 14.0; StataCorp LP, College Station, Tex). Existing guidelines have suggested that the cytological threshold for HRA referral should be any cytological abnormality, including ASC-US, LSIL, ASC-H, and HSIL. 29 The referral rate was defined as the percentage of individuals with any cytological abnormality, because these men would be referred to diagnostic HRA in a screening setting. We examined the performance characteristics of ASC-US-positive cytology in the detection of histologically diagnosed HSILs. In addition, we compared the performance characteristics in the detection of histological HSIL-AIN2 and HSIL-AIN3. The following test performance characteristics were calculated: sensitivity (the percentage of participants with histologically diagnosed HSILs who had any cytological abnormality), specificity (the percentage of participants with no histologically diagnosed HSILs who had negative cytology), positive predictive value (PPV) (the percentage of participants with a cytological abnormality who had histologically diagnosed HSILs), and negative predictive value (NPV) (the percentage of participants with negative anal cytology who had no histologically diagnosed HSILs).
Further analyses were performed to examine whether the performance of anal cytology differed in different subgroups as determined by 1) participants' characteristics, including age and HIV status; 2) the nature of the lesion, including the extent of histological HSIL and the number of biopsies taken; and 3) sample cellular composition, including the presence of rectal columnar cells and/or squamous metaplastic cells. For age-associated performance, participants were regrouped into those aged 35 to 44 years, 45 to 49 years, 50 to 54 years, and 55 years by approximately equal numbers in each age group. The extent of HSIL disease was measured by the number of octants of the anal mucosa in which HSIL was detected on biopsy. The octants were described as anterior, posterior, left and right anterior, left and right posterior, and left and right lateral. Performance was compared between those men who had HSIL affecting a single octant and those who had HSIL affecting multiple octants.
RESULTS
The median age of the 617 SPANC participants was 49 years (range, 35-79 years). Nearly all men (95.3%) identified as gay or homosexual. Greater than one-third (35.7%) of the men were HIV positive. The great majority of these men (93.6%) were currently receiving antiretroviral treatment, reported an undetectable viral load (89.5%), and had a clusters of differentiation 4 (CD4) count of >than 350 cells/lL (88.0%).
Twenty-nine men (4.7%) whose first and repeat cytology tests were unsatisfactory were excluded, including 1 man (0.2%) who was unable to tolerate HRA. A total of 588 participants had both cytological and histological assessment results available. In these remaining 588 men, anal cytology results were as follows: negative in 241 (41.0%), ASC-US in 103 (17.5%), LSIL in 47 (8.0%), ASC-H in 88 (15.0%), and HSIL in 109 (18.5%) ( Table 2) . Hence, when using any cytological abnormality as the threshold, the referral rate was 59%.
Based on HRA-guided biopsy in the 588 men with a satisfactory cytology result, the histological results were as follows: negative for SIL in 136 (23.1%), LSIL in 146 (24.8%), HSIL-AIN2 in 49 (8.3%), and HSIL-AIN3 or worse in 142 (24.2%, including 1 participant diagnosed with squamous cell carcinoma). In addition, 115 participants (19.6%) had a visually normal HRA and therefore did not have a biopsy taken. The correlation between the cytological and histological results is shown in Table 2 .
Anal Cytology Performance
Predicting histological HSIL Performance characteristics at the threshold of any anal cytological abnormality in the detection of histological HSIL were as follows: sensitivity of 83.2% (95% confidence interval [95% CI], 77.2%-88.2%), specificity of 52.6% (95% CI, 47.6%-57.6%), PPV of 45.8% (95% CI, 40.5%-51.2%), and NPV of 86.7% (95% CI, 81.8%-90.7%) ( Table 3) .
Performance in relation to participants
There were no differences with regard to test sensitivity (P 5 .924) and specificity (P 5 .116) between HIVpositive and HIV-negative men, but because HIV-positive men had more cytological abnormalities, they had a significantly higher referral rate (66.2% vs 54.9%; P 5 .007), a higher PPV (P 5 .013), and a lower NPV (P 5 .027) compared with HIV-negative men.
In relation to participants' age, there was a trend toward a decreased referral rate in older men, but this did not reach the significance level (61.6% in those aged <45 years and 56.1% in those aged >55 years; P for trend 5.131). There were trends toward increased sensitivity, specificity, PPV, and NPV with increasing age and this was statistically significant for specificity (P for trend 5.041).
Performance in relation to lesion Sensitivity was higher in men who had histological HSIL affecting >1 octant compared with those with HSIL present in 1 octant only (92.9% vs 77.7%; P 5 .010). Sensitivity also was higher in men who had more biopsies obtained (P for trend 5.077), but this was accompanied by a significant decrease in specificity (P for trend <.001) ( Table 3) .
Performance in relation to sample cellular composition
Cytological slides with the presence of 10 metaplastic cells were found to have significantly higher sensitivity (87.5% vs 70.2%; P 5 .007) but lower specificity (48.3% vs 64.2%; P 5 .005) than those with <10 metaplastic cells present. In contrast, the presence of columnar cells was not found to be associated with performance (P 5 .583 for sensitivity and P 5 .490 for specificity comparison) ( Table 3) .
Comparison of test performance in the detection of HSIL-AIN2 and HSIL-AIN3
A comparison of performance characteristics in the detection of HSIL-AIN2 and HSIL-AIN3 is shown in Table 4 . Anal cytology had a significantly higher sensitivity (P 5 .015) and PPV (P<.001) in detecting AIN3 than in detecting AIN2. In relation to HIV status, the NPV was significantly lower in HIV-positive compared with HIVnegative participants in the detection of AIN2 (P 5 .024), and the PPV was significantly higher in HIV-positive than in HIV-negative participants in the detection of AIN3 (P 5 .004).
DISCUSSION
Among homosexual men mainly recruited from community-based settings in Sydney, 59% had abnormal cytology and 35% had histological HSIL. The overall sensitivity of liquid-based anal cytology in the detection of histological HSIL was just above 80%, and the specificity was 53%. The sensitivity and specificity did not differ between HIV-positive and HIV-negative men, although the PPV was significantly higher (53.9% vs 40.3%) and the NPV was lower (79.2% vs 89.9%) in the men who were HIV positive. The specificity of anal cytology increased with age. The sensitivity increased significantly in those with HSILs affecting more octants and those from whom more biopsies were obtained. The performance of anal cytology is subject to operational and methodological variations. [16] [17] [18] 30 In interpreting the findings of the test performance of anal and cervical cytology, the histological diagnoses arising from HRA-guided and colposcopy-guided biopsies are Original Article traditionally accepted as the "gold" standard. [30] [31] [32] [33] However, there is evidence that HRA is technically more difficult than colposcopy. There are convoluted mucosal folds of the anal canal, and performance characteristics of HRA also vary with the training and experience of the anoscopist. 20, 34, 35 For these reasons, it is accepted that HRAguided biopsy is more likely to miss an existing HSIL than is cervical colposcopy. 36 Thus, some positive cytological findings in which no histological HSIL is found may represent a false-negative HRA rather than a false-positive cytology. If this is the case, studies such as ours may underestimate true specificity. In the current study, approximately one-third of cytological HSILs were not confirmed by HRA-guided biopsy at baseline. Future analyses have been planned to determine how this varied by anoscopist experience, and whether histological HSIL was diagnosed at the next study visit in these men. Recent studies in which liquid-based screening cytology and diagnostic HRA were performed on all participants generally reported sensitivities comparable to those of the current study, but lower specificities. [19] [20] [21] [22] [23] [24] In 3
clinic-based studies conducted in the United Kingdom, the United States, and Canada, the reported sensitivity ranged from 81% to 89% and the specificity ranged from 37% to 39%. 19, 21, 22 Similarly, a recent Spanish clinic-based study of 101 patients reported a sensitivity of 83% and a specificity of 41%. 24 Conversely, a Thai clinic-based study of 246 patients reported a substantially lower sensitivity of 19% and a much higher specificity of 88%. 23 Participants in the Thai study were much younger, with a mean age of 29 years, whereas the other studies involved older participants with a mean/median age ranging from the late 30s to the early 50s. The difference in participant age composition and variations in clinical experience in anal cytology and HRA may have contributed to the differences in the reported sensitivities and specificities. The sensitivity of liquid-based anal cytology in the detection of HSIL is similar to that of cervical cytology at approximately 80%, but the specificity is much lower compared with the latter, which is usually close to 90%. 37 However, it is important to note that cervical cytology has a higher threshold for immediate referral in routine practice in most countries with organized screening programs, including Australia. This threshold is usually ASC-H. Although histological HSIL was most common in those with cytological HSIL (67%), between 28% (ASC-US) and 48% (ASC-H) of those with less severe cytological abnormalities had histologically confirmed HSIL in the current study. This suggests that increasing the referral threshold in anal cytology is imprudent when the population at risk is comprised of homosexual men.
To the best of our knowledge, the relation between HIV status and anal cytology performance is inconsistent across studies. The current study found nearly identical sensitivity between HIV-positive and HIV-negative participants whereas the specificity was nonsignificantly higher in the latter group. A study of 125 homosexual men identified through random digit dialing in San Francisco found the specificity was significantly higher in HIV-negative compared with HIV-positive men (76% vs 47%; P 5 .02). 20 It is interesting to note that the aforementioned UK study found no association between sensitivity and HIV status. Rather, a CD4 count of <400 cells/lL was identified as a strong predictor of higher sensitivity. 21 Because only 25 of the HIV-positive men in the current study (12%) had a recent CD4 count of <350 cells/lL, we were unable to perform a meaningful analysis of the effect of CD4 count on test performance. Similar to the current study, an association between improved specificity and increasing age has been observed in cervical cytology, 38 but to our knowledge it has not been previously documented in anal cytology. In men with more frequent acute or transient HPV infections that produce LSILs, specificity may be expected to be lower than among those with fewer such LSILs. This is because cytological abnormalities can reflect the presence of either histological LSIL or HSIL. When cytology is abnormal due to histological LSIL, this result is regarded as being falsepositive because no histological HSIL is found and thus the specificity is lowered. We postulate that in older homosexual men, a higher percentage of HPV infections may be chronic due to their longer lifetime history of exposure. Therefore, in these men, abnormal cytological changes are more likely to be a true marker of histological HSIL, resulting in higher specificity. It is reassuring that anal cytology is capable of detecting anal cancer precursors with higher accuracy in older men, among whom interventions to prevent the development of cancer may be more urgent. Similar to a previous study, 21 we also found an increased sensitivity of anal cytology in the detection of HSIL in those in whom the disease affects a larger area. It is likely that abnormal squamous cells are more easily exfoliated from a larger HSIL surface area during anal sampling. An increasing number of biopsies also may be a marker of a higher burden of disease. Obtaining more biopsies also may contribute to a lower likelihood of missing high-grade lesions, therefore improving agreement between anal cytology and HRA. This has been shown to be true in the cervix. 39 If obtaining more biopsies is also a marker of an increased likelihood of any anal lesion being present and the lesion is LSIL, the cytological abnormality detected will be regarded as being false-positive, as previously discussed, thus lowering the specificity. The cell composition of the anal sample is another determinant of anal cytology performance. We found that the presence of 10 metaplastic cells was associated with higher sensitivity. Metaplastic cells originate from the transformation zone, the area in which most anal HSIL arises, and therefore it is not surprising that the presence of metaplastic cells predicts a higher sensitivity. Conversely, and consistent with another study, 12 the presence of columnar cells (derived from just superior to the transformation zone) was not found to be associated with anal cytology performance. Because the presence of metaplastic cells and columnar cells are not independent of each other, we plan to further investigate the importance of these 2 cell types.
As what to the best of our knowledge is the largest study published to date that is capable of assessing the performance of anal cytology, one of the strengths of the SPANC study is that the majority of participants were recruited from community-based settings. Thus, performance characteristics, particularly PPV and NPV (which are associated with disease prevalence), are more likely to be representative of homosexual men in general. Clinic-based cohorts tend to focus on HIV-positive men who have a higher prevalence of HSIL, which is associated with a higher PPV of the screening test. 40 In addition, p16 staining was universally applied to all lesions suspicious for histological HSIL-AIN2, a diagnosis that is prone to subjective operator bias and traditionally has poor reproducibility. 28, 29 In a SPANC substudy, a very high degree of interpathologist and intrapathologist diagnostic reproducibility was found partially due to the use of p16 staining. 41 To our knowledge, this is the first published study assessing the performance of anal cytology following the LAST recommendations. The performance characteristics in the detection of HSIL-AIN2 are presented separately from HSIL-AIN3 for ease of cross-study comparison. The other strength of the current study worth noting is that both anoscopists and pathologists were blind to the participants' medical history (except for HIV status for the anoscopists) at baseline. This is as would be the case when a screening program is implemented in a community-based setting.
One of the limitations of the current study is that the majority of anoscopists were newly trained by the lead anoscopist (R.J.H.) during the study. However, stringent training procedures (observing 50 HRA procedures followed by another 50 HRA procedures performed under supervision before contributing study data) ensured that all anoscopists were skilled at all necessary techniques in a standardized fashion to minimize operator bias. Furthermore, all anoscopists had regular reviews for quality assurance. As a sensitivity analysis, the performance characteristics were compared between the more experienced anoscopists (those who performed >200 HRAs) and those who were less experienced, and there were no significant differences noted between the 2 groups (data not shown).
Liquid-based anal cytology as an anal cancer screening test was found to have a higher specificity in older men, who generally have a higher cancer risk than their younger counterparts. However, the finding that close to 60% of men recruited largely from community-based settings have any cytology abnormality would result in a very high demand for referral HRA should a screening program in its current form be implemented. Given the invasive nature of HRA, this might hinder screening uptake in this high-risk population. Furthermore, the trained medical workforce may be unable to meet the demand for referral services, even in resource-rich countries such as Australia. The value of additional tests, such as HPV biomarkers, should be investigated as part of the development of an anal screening program. 
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